Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Handbook of Experimental Pharmacology|March 19, 2017
Mechanisms of Resistance in Multiple MyelomaAthanasios Papadas, Fotis AsimakopoulosAdvances in Experimental Medicine and Biology|August 27, 2020
Versican in the Tumor MicroenvironmentAthanasios Papadas, Fotis AsimakopoulosJournal of Virology|March 13, 2009
Cell-specific transduction of Prdm1-expressing lineages mediated by a receptor for avian leukosis virus subgroup BFotis Asimakopoulos, Harold E VarmusOncoimmunology|May 4, 2016
Deploying myeloid cells against myelomaJeffrey L Jensen, Chelsea Hope, Fotis AsimakopoulosAmerican Journal of Physiology. Cell Physiology|July 25, 2022
Matrix proteoglycans in tumor inflammation and immunityGauri Deb, Alexander Cicala, Athanasios Papadas, et al.The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|July 7, 2020
Versican and Versican-matrikines in Cancer Progression, Inflammation, and ImmunityAthanasios Papadas, Garrett Arauz, Alexander Cicala, et al.Journal of Leukocyte Biology|March 4, 2017
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma nicheFotis Asimakopoulos, Chelsea Hope, Michael G Johnson, et al.Leukemia & Lymphoma|October 11, 2022
Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myelomaChristopher D'Angelo, Sailendharan Sudakaran, Fotis Asimakopoulos, et al.Journal for Immunotherapy of Cancer|July 5, 2018
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkersMuhammad Umair Mushtaq, Athanasios Papadas, Adam Pagenkopf, et al.The Journal of Biological Chemistry|December 4, 2015
Loss of SIRT3 Provides Growth Advantage for B Cell MalignanciesWei Yu, Ryan A Denu, Kimberly A Krautkramer, et al.Pageof 4